Managed Care Perspectives on CKD-Anemia: Optimizing Clinical Outcomes and Mitigating Financial Toxicity with Intravenous Iron Therapies
This timely, adaptive, and dynamic educational activity is targeted to managed care professionals, physicians, and specialty pharmacists attending the 2021 Academy of Managed Care Pharmacy (AMCP) Nexus meeting. Activity attendees will be given the opportunity to interact with world-renowned expert faculty across all clinically relevant aspects of iron deficiency anemia (IDA) management in chronic kidney disease (CKD). The session will begin with a thorough review of iron metabolism and absorption principles, including the practical distinctions between absolute and functional iron deficiency, and the impact of that distinction on treatment. An exhaustive appraisal of the multifactorial etiologies and foundational pathophysiology of anemia in CKD will follow, with a central emphasis on the role of hepcidin in a hyperinflammatory disease state like CKD and how that process should lead to preferential use of intravenous (IV) iron versus oral iron modalities in these patients. Completed, ongoing, and planned clinical trials of IV iron for IDA management, both specific to CKD and in the general populace, will be examined, and newer formulations with nanoparticle drug design will be highlighted, especially their substantively improved safety profile over the older high-molecular weight (HMW) dextran products. Finally, using real-world patient cases, expert key insights on how and why IV iron possesses the capacity to revolutionize treatment of IDA in CKD, the importance of nanomedicine design, budgetary impact analyses (BIA) of IV iron products, with an emphasis on ESA dose reduction and avoidance of transfusions, natural history of IV iron agents to-date and the critical distinguishing factors among currently-approved agents, and lastly, the provision of evidence-based algorithms for optimal diagnosis, evaluation, and safe, cost-efficient treatment of IDA in CKD.
Presented by Creative Educational Concepts and Supported by an Independent Educational Grant from American Regent.
This adaptive educational initiative is targeted to managed care pharmacists and pharmacy directors attending the 2021 AMCP Nexus Meeting.
- Understand the multifactorial etiologies and complex pathophysiology of iron deficiency anemia (IDA) in chronic kidney disease (CKD), and evaluate the role of inflammation and hepcidin on iron supplementation strategies.
- Appraise completed, ongoing, and planned clinical trials of IV iron therapies for IDA management in CKD, and identify how the innovative nanoparticle design of next-generation IV iron products dramatically improves upon the safety profiles of high-molecular weight (HMW) dextran agents, with anaphylaxis rates as low as 0.1%.
- Using a real-world case-based format, interpolate the expanding scientific knowledge base regarding the impact of inflammation and hepcidin on iron availability and utilization, especially in a hyperinflammatory state like CKD, and the resultant rationale for preferential treatment with IV iron vs. oral iron.
CEC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.5 contact hours (.10 CEUs) of continuing pharmacy education credit JA
Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation